- Email: [email protected]
P1.05-062 Is Lung Microwave Thermoablation a Valid Alternative to Surgery in High Risk Patients? A Propensity Match Analysis
January 2017
Abstracts
S653
mortality. For surgery and SABR, overall survival was worse for patients with ILD compared to those without ILD. Keywords: interstitial lung disease, Surgery, stereotactic ablative radiation therapy, non-small cell lung cancer
patients affected by Stage I NSCLC or lung metastasis, lung MW thermoablation is confirmed as a valid alternative treatment in high risk patients. Randomized prospective studies are mandatory. Keywords: Microwave; Thermoablation; Lobectomy
P1.05-062 Is Lung Microwave Thermoablation a Valid Alternative to Surgery in High Risk Patients? A Propensity Match Analysis
P1.05-063 Multicenter Observational Study of Patients with Resected Early-Staged NSCLC, Who Were Excluded from an Adjuvant Chemotherapy Trial
Topic: Miscellaneous
Topic: Miscellaneous
Paolo Mendogni,1 Davide Tosi,1 Alessandro Palleschi,1 Lorenzo Rosso,1 Ilaria Righi,1 Matteo Montoli,1 Francesco Damarco,1 Claudia Bareggi,2 Cristina Marenghi,3 Mario Nosotti1 1 Thoracic Surgery and Lung Transplantation Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan/Italy, 2Oncology, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan/Italy, 3 Anesthesiology and Critical Care, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan/Italy
Tomoyuki Hishida,1 Masahiro Tsuboi,1 Kiyotaka Yoh,2 Kazuya Takamochi,3 Hiroyuki Sakurai,4 Yasushi Goto,5 Takehiro Shukuya,6 Yasuo Ohashi,7 Hideo Kunitoh8 1 Thoracic Surgery, National Cancer Center Hospital East, Chiba/Japan, 2Thoracic Oncology, National Cancer Center Hospital East, Chiba/Japan, 3General Thoracic Surgery, Juntendo University School of Medicine, Tokyo/Japan, 4 Thoracic Surgery, National Cancer Center Hospital, Tokyo/Japan, 5Thoracic Oncology, National Cancer Center Hospital, Tokyo/Japan, 6Thoracic Oncology, Juntendo University School of Medicine, Tokyo/Japan, 7Chuo University, Tokyo/Japan, 8Medical Oncology, Japanese Red Cross Medical Center, Tokyo/Japan
Background: Surgery is considered the best treatment in Stage I non-small cell lung cancer. Local nonesurgical therapies (radiotherapy, thermoablation) are becoming valid alternative to surgery in high risk patients (poor cardiac or pulmonary function, elderly patients). Methods: Patients submitted in our Department to Microwave thermoablation (MW) were compared with a cohort of patient submitted to lung lobectomy in the same period of time, abstracted from our database with a propensity match method. The study was retrospective on data recorded prospectively. Primary endpoint was overall survival. Results: From June 2009 to October 2014 in our Department, 36 patients underwent MW for Stage I nonsmall cell lung cancer (NSCLC) or lung metastasis. From our database were abstracted 41 patients with a propensity match method, submitted to lung lobectomy. Two groups were comparable by age, diagnosis, stage and gender. MW group resulted elder than Surgery group (75,5 vs 72,2 years; p<0,001). Lesion diameter was greater in MW group (20,9 vs 26,5 cm; p<0,001). Overall survival, analyzed by actuarial survival curve, was comparable (Logrank test p¼0,2). Conclusion: In our experience, in a propensity match evaluation, lung MW thermoablation resulted non inferior than lung lobectomy in terms of overall survival. Even though surgery is still considered the first choice in
Background: From Nov. 2008 to Dec. 2013, the Japan Clinical Oncology Group (JCOG) conducted a randomized phase III trial (JCOG0707), which compared the survival benefit of UFT and S-1 for completely resected pathological (p-) stage I (T1>2 cm and T2 in the 6th TNM classification) NSCLC and a total of 963 patients were enrolled. Recently, there is a growing concern that those who participated in clinical trials are highly selected and do not represent the “real-world” population. Hereby, we conducted a multicenter observational study of patients excluded from JCOG0707 trial during the study period. Methods: We retrospectively collected and analyzed the patients’ backgrounds, tumor profiles, post-surgical treatment of the patients who underwent R0 resection of p-stage I (T1>2cm and T2 in TNM 6th) NSCLC by lobectomy or larger lung resection but were excluded from JCOG0707 from Japanese multi-centers. Results: Of the 48 institutions which took part in JCOG0707, 34 (enrolling 917 or 95.2% of all JCOG0707 patients) participated in this multicenter study, and 5006 patients were enrolled. Among them, 2617 (52.3%) patients fulfilled the eligibility criteria, but were not enrolled to JCOG0707 mainly due to patients’ decline
Abstracts
S653
mortality. For surgery and SABR, overall survival was worse for patients with ILD compared to those without ILD. Keywords: interstitial lung disease, Surgery, stereotactic ablative radiation therapy, non-small cell lung cancer
patients affected by Stage I NSCLC or lung metastasis, lung MW thermoablation is confirmed as a valid alternative treatment in high risk patients. Randomized prospective studies are mandatory. Keywords: Microwave; Thermoablation; Lobectomy
P1.05-062 Is Lung Microwave Thermoablation a Valid Alternative to Surgery in High Risk Patients? A Propensity Match Analysis
P1.05-063 Multicenter Observational Study of Patients with Resected Early-Staged NSCLC, Who Were Excluded from an Adjuvant Chemotherapy Trial
Topic: Miscellaneous
Topic: Miscellaneous
Paolo Mendogni,1 Davide Tosi,1 Alessandro Palleschi,1 Lorenzo Rosso,1 Ilaria Righi,1 Matteo Montoli,1 Francesco Damarco,1 Claudia Bareggi,2 Cristina Marenghi,3 Mario Nosotti1 1 Thoracic Surgery and Lung Transplantation Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan/Italy, 2Oncology, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan/Italy, 3 Anesthesiology and Critical Care, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan/Italy
Tomoyuki Hishida,1 Masahiro Tsuboi,1 Kiyotaka Yoh,2 Kazuya Takamochi,3 Hiroyuki Sakurai,4 Yasushi Goto,5 Takehiro Shukuya,6 Yasuo Ohashi,7 Hideo Kunitoh8 1 Thoracic Surgery, National Cancer Center Hospital East, Chiba/Japan, 2Thoracic Oncology, National Cancer Center Hospital East, Chiba/Japan, 3General Thoracic Surgery, Juntendo University School of Medicine, Tokyo/Japan, 4 Thoracic Surgery, National Cancer Center Hospital, Tokyo/Japan, 5Thoracic Oncology, National Cancer Center Hospital, Tokyo/Japan, 6Thoracic Oncology, Juntendo University School of Medicine, Tokyo/Japan, 7Chuo University, Tokyo/Japan, 8Medical Oncology, Japanese Red Cross Medical Center, Tokyo/Japan
Background: Surgery is considered the best treatment in Stage I non-small cell lung cancer. Local nonesurgical therapies (radiotherapy, thermoablation) are becoming valid alternative to surgery in high risk patients (poor cardiac or pulmonary function, elderly patients). Methods: Patients submitted in our Department to Microwave thermoablation (MW) were compared with a cohort of patient submitted to lung lobectomy in the same period of time, abstracted from our database with a propensity match method. The study was retrospective on data recorded prospectively. Primary endpoint was overall survival. Results: From June 2009 to October 2014 in our Department, 36 patients underwent MW for Stage I nonsmall cell lung cancer (NSCLC) or lung metastasis. From our database were abstracted 41 patients with a propensity match method, submitted to lung lobectomy. Two groups were comparable by age, diagnosis, stage and gender. MW group resulted elder than Surgery group (75,5 vs 72,2 years; p<0,001). Lesion diameter was greater in MW group (20,9 vs 26,5 cm; p<0,001). Overall survival, analyzed by actuarial survival curve, was comparable (Logrank test p¼0,2). Conclusion: In our experience, in a propensity match evaluation, lung MW thermoablation resulted non inferior than lung lobectomy in terms of overall survival. Even though surgery is still considered the first choice in
Background: From Nov. 2008 to Dec. 2013, the Japan Clinical Oncology Group (JCOG) conducted a randomized phase III trial (JCOG0707), which compared the survival benefit of UFT and S-1 for completely resected pathological (p-) stage I (T1>2 cm and T2 in the 6th TNM classification) NSCLC and a total of 963 patients were enrolled. Recently, there is a growing concern that those who participated in clinical trials are highly selected and do not represent the “real-world” population. Hereby, we conducted a multicenter observational study of patients excluded from JCOG0707 trial during the study period. Methods: We retrospectively collected and analyzed the patients’ backgrounds, tumor profiles, post-surgical treatment of the patients who underwent R0 resection of p-stage I (T1>2cm and T2 in TNM 6th) NSCLC by lobectomy or larger lung resection but were excluded from JCOG0707 from Japanese multi-centers. Results: Of the 48 institutions which took part in JCOG0707, 34 (enrolling 917 or 95.2% of all JCOG0707 patients) participated in this multicenter study, and 5006 patients were enrolled. Among them, 2617 (52.3%) patients fulfilled the eligibility criteria, but were not enrolled to JCOG0707 mainly due to patients’ decline